Avalo Therapeutics (NASDAQ:AVTX) and China SXT Pharmaceuticals (NASDAQ:SXTC) Head-To-Head Review

Avalo Therapeutics (NASDAQ:AVTXGet Free Report) and China SXT Pharmaceuticals (NASDAQ:SXTCGet Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, analyst recommendations, institutional ownership, risk and valuation.

Profitability

This table compares Avalo Therapeutics and China SXT Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Avalo Therapeutics N/A -442.16% 122.99%
China SXT Pharmaceuticals N/A N/A N/A

Earnings & Valuation

This table compares Avalo Therapeutics and China SXT Pharmaceuticals”s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Avalo Therapeutics $1.92 million 43.40 -$31.54 million N/A N/A
China SXT Pharmaceuticals $1.93 million 0.83 -$3.10 million N/A N/A

China SXT Pharmaceuticals has higher revenue and earnings than Avalo Therapeutics.

Risk & Volatility

Avalo Therapeutics has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500. Comparatively, China SXT Pharmaceuticals has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500.

Insider & Institutional Ownership

87.1% of Avalo Therapeutics shares are held by institutional investors. Comparatively, 5.0% of China SXT Pharmaceuticals shares are held by institutional investors. 0.3% of Avalo Therapeutics shares are held by insiders. Comparatively, 4.0% of China SXT Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Avalo Therapeutics and China SXT Pharmaceuticals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avalo Therapeutics 0 1 2 0 2.67
China SXT Pharmaceuticals 0 0 0 0 0.00

Avalo Therapeutics currently has a consensus price target of $40.00, suggesting a potential upside of 398.75%. Given Avalo Therapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Avalo Therapeutics is more favorable than China SXT Pharmaceuticals.

Summary

Avalo Therapeutics beats China SXT Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

About Avalo Therapeutics

(Get Free Report)

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

About China SXT Pharmaceuticals

(Get Free Report)

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.